Parvovirus B19 status in liver, kidney and pancreas transplant candidates: A single center experience

Table 1 Study population characteristics (n = 131)

Item	Value
Age, yr (mean ± SD)	53.27 ± 12.71
Gender
Male	93 (70.9%)
Female	38 (29.1%)
Transplant type
Liver	90 (68.7%)
Kidney	36 (27.5%)
SPKT	4 (3.0%)
SLKT	1 (0.8%)
Virology results
B19V DNA positive	0 (0%; one-sided 97.5% CI: 0-2.8)
B19V IgM positive	0 (0%; one-sided 97.5% CI: 0-2.8)
IgG B19V positive	101 (77.1%; 95% CI: 68.9-83.9)

SPKT: Simultaneous pancreas/kidney transplantation; SLKT: Simultaneous liver/kidney transplantation; CI: Confidence interval.

Table 2 Parvovirus B19 IgG seroprevalence rates in transplant candidates

Characteristics	Tested, n (%)	IgG positive, n (%)	χ2	P value
Gender			0.104	0.748
Male	93 (71.0)	71 (76.3)
Female	38 (29.0)	30 (78.9)
Age, yr			0.619	0.734
< 30	6 (5.8)	4 (66.6)
30-59	56 (54.4)	45 (80.4)
> 60	41 (39.8)	32 (78.1)
Transplant type			5.297	0.151
Liver	90 (68.7)	70 (77.8)
Kidney	36 (27.5)	29 (80.6)
SPKT	4 (3.0)	2 (50.0)
SLKT	1 (0.8)	0 (0)
IS before transplantation			0.498	0.780
Yes	16 (18.2)	13 (81.3)
No	72 (81.8)	55 (76.4)
Dialysis modality				0.3721
HD	38 (95)	27 (71.1)
PD	2 (5)	2 (100)

¹Fisher's exact test. SPKT: Simultaneous pancreas/kidney transplantation; SLKT: Simultaneous liver/kidney transplantation; IS: Immunosuppression; HD: Hemodialysis; PD: Peritoneal dialysis.